Primary Fibromyalgia Syndrome and 5-Hydroxy-L-Tryptophan: A 90-Day Open Study

Abstract

The efficacy and tolerability of 5-hydroxy-L-tryptophan (5- HTP) were studied in an open 90-day study in 50 patients affected by primary fibromyalgia syndrome. When all the clinical variables studied throughout the trial (number of tender points, anxiety, pain intensity, quality of sleep, fatigue) were compared with baseline results, they all showed a significant improvement (P< 0.001). The overall evaluation of the patient condition assessed by the patient and the investigator indicated a ‘good’ or ‘fair’ clinical improvement in nearly 50% of the patients during the treatment period. A total of 15 (30%) patients reported side-effects but only one patient was withdrawn from the treatment for this reason. No abnormality in the laboratory evaluation was observed. It is concluded that 5-HTP is effective in improving the symptoms of primary fibromyalgia syndrome and that it maintains its efficacy throughout the 90-day period of treatment.

Keywords

5-Hydroxy-1-tryptophan Primary fibromyalgia syndrome

Get full access to this article

View all access options for this article.

References

Bennett

Fibrositis. In: Textbook of Rheumatology ( Kelly

Harris

Ruddy

eds). Philadelphia: WB Saunders, 1989; pp 541–553.

Goldenberg

Fibromyalgia, chronic fatigue syndrome and myofascial pain syndrome. Curr Opin Rheumatol 1991; 3: 247–258.

Payne

Leavitt

Garron

Fibrositis and psychological disturbance. Arthritis Rheum 1982; 25: 213–217.

Moldofsky

Scaresbrick

England

Musculoskeletal symptoms and non-REM sleep disturbance in patients with ‘fibrositis syndrome’ and healthy subjects. Psychosom Med 1975; 4: 341–351.

Bengtsson

Henriksson

Larsson

Reduced high energy phosphate levels in the painful muscles of patients with primary fibromyalgia. Arthritis Rheum 1986; 29: 817–821.

Dinerman

Goldenberg

Felson

A prospective evaluation of 118 patients with fibromyalgia syndrome: prevalence of Raynaud's phenomenon, sicca symptoms and low complement and Ig deposition in the dermal – epidermal junction. J Rheumatol 1986; 13: 368–373.

Vaeroy

Helle

Forre

Elevated CFS levels of substance P and high incidence of Raynaud's phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 1988; 15: 21–26.

Yunus

Denko

Masi

Plasma beta-endorphin in primary fibromyalgia syndrome; a controlled study. J Rheumatol 1986; 13: 183–186.

Moldofsky

Warsh

Plasma tryptophan and musculoskeletal pain in non-articular rheumatism. Pain 1978; 5: 65–71.

10.

Russell

Michalek

Vaprio

Serum amino acids in fibrositis/fibromyalgia syndrome. J Rheumatol 1989; 16 (suppl 19): 158–163.

11.

Goldenberg

A review of the role of tricyclic medications in the treatment of fibromyalgia syndrome. J Rheumatol 1989; 16 (suppl 19): 137–139.

12.

Caruso

Sarzi Puttini

Boccassini

Double-blind study of dothiepin versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res 1987; 15: 154–159.

13.

Moldofsky

Lue

The relationship of alpha and delta EEG frequencies to pain and mood in ‘fibrositis' patients treated with chloropromazine and L-tryptophan. Electroencephalgr Clin Neurophysiol 1980; 50: 71–80.

14.

Caruso

Sarzi Puttini

Cazzola

Double-blind study of 5-hydroxy-tryptophan versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res 1990; 18: 201–209.

15.

Hertzman

Blevins

Mayer

Association of the eosinophilia – myalgia syndrome with the ingestion of tryptophan. N Engl J Med 1990; 322: 869–873.

16.

Belongia

Hedberg

Gleich

An investigation of the cause of the eosinophilia – mylagia syndrome associated with tryptophan use. N Engl J Med 1990; 323: 357–365.

17.

Yunus

Masi

Calabro

Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. Semin Arthritis Rheum 1981; 11: 151 –171.

18.

Hertzman

Falk

Kilbourne

The eosinophilia – myalgia syndrome: the Los Alamos conference. J Rheumatol 1991; 18: 867–873.